Trial of Short Course Therapy in Elderly Patients with High Grade Non-Hodgkin's Lymphoma

Submission date	Recruitment status	☐ Prospectively registered
19/08/2002	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
19/08/2002	Completed	Results
Last Edited	Condition category	Individual participant data
08/04/2015	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)Scientific

Contact name

- - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers LY/SCT

Study information

Scientific Title

Trial of Short Course Therapy in Elderly Patients with High Grade Non-Hodgkin's Lymphoma

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

Interventions

- 1. PACEBO Regimen: Adriamycin, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin, cycle to be repeated every 14 days for four cycles.
- 2. PMitCEBO Regimen: Mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin, cycle to be repeated every 14 days for four cycles.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

PACEBO Regimen: Adriamycin, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin PMitCEBO Regimen: Mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone and septin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2000

Completion date

31/12/2005

Eligibility

Key inclusion criteria

- 1. Aged 60 to 85 years
- 2. Newly presenting high grade lymphoma presenting as:
- 2.1 Follicular lymphoma
- 2.2 Diffuse large cell lymphoma including immunoblastic
- 2.3 Diffuse mixed cell lymphoma Lymphoblastic and Burkitt's lymphoma are excluded
- 3. Stage IB-IV
- 4. Patients must be free from any other irreversible medical condition that would drastically limit their lifespan or prohibit the use of combination chemotherapy

Participant type(s)

Patient

Age group

Senior

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

UK Co-ordinating Committee for Cancer Research (UKCCCR)

Sponsor details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Sponsor type

Government

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Research organisation

Funder Name

Cancer organisations (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration